



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 179 442
A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 85113384.3

⑭ Date of filing: 22.10.85

⑮ Int. Cl.4: C 07 F 9/117
A 61 K 31/66, A 23 L 3/34

⑯ Priority: 23.10.84 SE 8405295
26.06.85 SE 8503164
26.06.85 SE 8503165

⑰ Date of publication of application:
30.04.86 Bulletin 86/18

⑱ Date of deferred publication of search report: 08.04.87

⑲ Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

⑳ Applicant: Sirén, Matti
Casa Camponi Via al Crespo
CH-6596 Gordola(CH)

㉑ Inventor: Sirén, Matti
Casa Camponi Via al Crespo
CH-6596 Gordola(CH)

㉒ Representative: Eitlie, Werner, Dipl.-Ing. et al,
Hoffmann, Eitlie & Partner Patentanwälte Arabellastrasse
4
D-8000 München 81(DE)

㉓ Stabilized composition containing inositoltriphosphate and method for stabilizing the composition.

㉔ A stabilized composition comprising an organic sub-
strate, such as a pharmaceutical or biological system subject
to degradation by oxidation and/or free radicals and a method
for production thereof.

ER 0 179 442 A3



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 179 442
A2

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 85113384.3

⑭ Date of filing: 22.10.85

⑮ Int. Cl. 4: C 07 F 9/117
A 61 K 31/66, A 23 L 3/34

⑯ Priority: 23.10.84 SE 8405295
26.08.85 SE 8503164
26.08.85 SE 8503165

⑰ Date of publication of application:
30.04.86 Bulletin 86/18

⑮ Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

⑲ Applicant: Sirén, Matti
Casa Camboni Via al Crespo
CH-6596 Gordola(CH)

⑳ Inventor: Sirén, Matti
Casa Camboni Via al Crespo
CH-6596 Gordola(CH)

㉑ Representative: Ettie, Werner, Dipl.-Ing. et al.
Hoffmann, Ettie & Partner Patentanwälte Arabellastrasse
4
D-8000 München 81(DE)

㉒ Stabilized composition containing inositoltriphosphate and method for stabilizing the composition.

㉓ A stabilized composition comprising an organic sub-
strate, such as a pharmaceutical or biological system subject
to degradation by oxidation and/or free radicals and a method
for production thereof.

EP 0 179 442 A2

0179442

Stabilized composition containing inositoltriphosphate and method for stabilizing the composition

The present invention relates to a stabilized composition comprising an organic substrate, such as a pharmaceutical or biological system subject to degradation by oxidation and/or free radicals, and a method for production thereof.

5 It is well-known that biological materials and pharmaceuticals often have a rather limited stability even if they are stored in a dark and cold space. Among the pharmaceuticals having such a low stability, insulin, vaccine, hyaluronic acid, intra-
10 lipid and prostaglandin can be mentioned. In addition, many other organic substrates susceptible to oxidative or free radical degradation are well-known to those skilled in the art and include e.g. fats, oils, ethylenically unsaturated compounds, derivatives and polymers e.g. acrylate compounds and resins, polyvinylacetate, polyvinyl-
15 pyrrolidone, vinylacetate, vinylpyrrolidone and the like.

It is well-known that the formation of free radicals during storing and/or use of many pharmaceuticals and biological materials causes a degradation of these products. The free radicals
20 namely cause an oxidation, which in its turn results in a degradation of the pharmaceutical or the biological material. Similar mechanisms are responsible for the lack of stability of other organic substrates, such as those mentioned above.

25 Accordingly, the presence of free radicals can explain why hyaluronic acid for example is effective at application of eyes but not at injection in joints for treatment of rheumatism. Free radicals are formed in the eyes to a slight extent. However, on the other hand, in the joints, free radicals are
30 formed in a considerable amount. Therefore, the hyaluronic acid is broken down or degraded by free radicals in the joint fluids before it has given the desired effect.

In addition to the negative effect on the stability of pharmaceuticals and biological materials, free radicals can also increase the toxicity of said products, which of course is a very serious problem.

A very intensive research effort has been carried out for many years to find an effective and non-toxic stabilizer for organic substrates, such as pharmaceuticals and biological materials. In general, said work has not given the desired result.

5

In the U.S. patent 2,723,938 another kind of stabilization than that according to the present invention is disclosed. Thus, according to said patent the use of inositolhexaphosphates (IP_6), especially sodium phytate for stabilizing dispersability 10 of aqueous suspensions of insoluble penicillin even after prolonged storage is shown. The use of said sodium phytate is said to insure that brief manual shaking will restore a state of complete and uniform dispersion of the penicillin. However, 15 no effectiveness in stabilization against oxidative degradation caused by free radicals is reported. When compared with IP_3 stabilizers of this invention, IP_6 is found to be less effective as a stabilizer against degradation of organic substrates. In addition, the use of IP_6 is also seriously limited because 20 of the impact on the mineral balance in animals including humans, thus limiting use thereof in compositions to be administrated to human hosts.

According to present invention a stabilized composition comprising 25 organic substrates such as pharmaceuticals and biological systems has been provided. The stabilized composition is characterized in that it contains inositoltriphosphate, IP_3 , in a stabilizing amount.

The appropriate stabilizing amount of IP_3 should be determined 30 by routine experimentation to obtain optimum values. For example accelerated aging test can be performed with a test substrate at various levels of IP_3 and the optimum level be determined thereby. In general, at least 0.001 % by weight of IP_3 based 35 on the weight of the composition will provide some beneficial effect. Usually from 0.01-2 % by weight will be employed.

The stabilizer is mainly intended to be used against degradation caused by free radicals. Such free radicals can be formed in different ways, for instance by metals, such as iron, aluminium and cadmium, and by radiation.

0179442

However, the stabilizer is intended also to be used against degradation caused by oxidation and hydrolysis. The oxidation can be caused by free radicals as mentioned above. However, oxidation can depend on other mechanisms too. Therefore, the invention covers stabilization against oxidation, hydrolysis or radiation, whatever mechanism lies behind said reaction.

The stabilizer can be used for stabilizing many different pharmaceuticals, of which insulin, vaccines, hyaluronic acid, intra-
10 lipid, prostaglandin and hormones can be mentioned.

Also a lot of different biological materials can be stabilized according to the invention. However, preferably the biological material is selected from DNA, recombinant DNA, RNA, nucleic acids, biological tissue, transplants, carbohydrates, lipids, membranes, proteins, such as enzymes and plasma proteins, culture media for micro-organisms, cell culture media, blood containing substrates, blood for transfusion, nutrient substrates, insemination media, micro-organisms, seeds, plant parts, spores, fruits and food stuffs.

20 According to one suitable method for the production of IP_3 a material containing IP_6 is broken down enzymatically with phytase enzyme. The IP_6 can be provided either as pure material or in the form of an IP_6 containing source, such as wheat bran. 25 Phytase enzyme can be found for instance in plants, seeds and micro-organisms.

By the enzymatic treatment of the IP_6 a hydrolysis takes place resulting in a mixture of different lower inositolphosphates, 30 i.e. inositolpentaphosphate (IP_5), inositoltetraphosphate (IP_4), inositoltriphosphate (IP_3), inositoldiphosphate (IP_2) and inositol- 1 monophosphate (IP_1).

Usually, the hydrolysis is carried out at a temperature of 20-70°C 35 and a pH of 4 to 8. The hydrolysis is suitably stopped when the liberation of about 30-60 % of the total ester phosphorus has been achieved. At said stage a high proportion of the desired IP_3 isomer or isomers has been formed by hydrolysis of the IP_6 containing material.

The mixture of inositolphosphates obtained may hereafter be separated by chromatography to isolate the IP_3 -containing fraction. Preferably, this is made in a column. If the IP_3 fraction contains more than one isomer, these isomers are separated in another subsequent chromatographic separation step.

The IP_3 can be obtained as a salt or as an acid thereof. The salt form is preferred, since it is easier to produce in pure and concentrated form than the acid.

The salt form of the IP_3 isomer is readily obtainable from the acid form using standard procedures. Thus, there can be prepared salts, such as alkali metal and alkaline earth metal salts, e.g. lithium, sodium, potassium, calcium or magnesium. However, also the aluminium, zinc and iron salts are very useful as well as the NH_4^+ and organic amine salts. Exemplary amines are triethanolamine, diethanolamine, triisopropanol-ethanolamine, tetrabutylamine and cyclohexylamine. Also other salts might be used. Especially preferred salts are those which are physiologically acceptable.

25 The invention is not restricted to any particular isomer of IP_3 . Consequently, all individual isomers of IP_3 and mixtures thereof are included in the above definition, IP_3 . However, preferably the stabilized composition comprises at least one of D-myoinositol-1.2.6-triphosphate, D-myoinositol-1.2.5-triphosphate, 30 myo-inositol-1.2.3-triphosphate, D-myoinositol-1.4.5-triphosphate and L-myoinositol-1.3.4-triphosphate. Of these isomers D-myoinositol-1.2.6-triphosphate is preferred.

35 When using yeast, preferably baker's yeast as a phytase source, only one isomer of IP_3 is obtained; namely D-myoinositol-1.2.6-triphosphate. Especially when the composition comprises pharmaceuticals it is generally preferred to use the isomer or isomers of IP_3 in substantially pure form. The stabilizer component of the composition can consist wholly or essentially of IP_3 .

40 The stabilizer is non-toxic and very efficient.

0179442


Sometimes the composition can also contain a minor amount of other inositolphosphates, especially inositoldiphosphate, IP_2 and inositoltetraphosphate, IP_4 in addition to IP_3 . This is particularly the case where seeds, plant parts, spores, fruits and foodstuff are to be stabilized according to the invention. IP_2 and IP_4 can be presented in acid as well as in salt form.

The IP_3 -isomers mentioned above have the following formulas:

10

D-myoinositol-1,2,6-triphosphate of the formula

15



20

25


30

35

where X is hydrogen, at least one univalent, divalent or multivalent cation, or a mixture thereof, n is the number of ions, and z is the charge of the respectively ion;


5 D-myoinositol-1.2.5-triphosphate of the formula

10



where X, n and z have the above mentioned meaning;
myoinositol-1.2.3-triphosphate of the formula


15



20

where X, n and z have the above mentioned meaning;
L-myoinositol-1.3.4-triphosphate of the formula


25



30

where X, n and z have the above mentioned meaning; and
D-myoinositol-1.4.5-triphosphate of the formula

35



where x, n and z have the above meaning.

0179442

In each of the above formulas n ranges between 6 to 1 inclusive and z ranges from 1 to 6 inclusive. Preferably, n is between 5 to 6 inclusive and z is 3, 2 or 1.

The invention will be explained further in detail in connection with the embodiment examples below, of which examples 1-5 show that IP_3 prevents or reduces the formation of free radicals. 10 Example 6 illustrates preservation of some fruits and vegetables at the addition of IP_3 . Example 7 shows that an addition of IP_3 to an enzyme gives a remarkable retention of the enzyme activity at storage. Examples 8-14 show production of IP_3 and the separation thereof into different isomers.

15

20

25

30

35

5 An aqueous solution containing 0.3 mM FeCl_3 , 5.0 mM ethylenediaminetetraacetic acid (EDTA), 50 mM tris (hydroxymethyl)-aminomethan (TRIS) and 1.0 M NaN_3 was prepared. In the solution the complex Fe^{3+} - EDTA - N_3 was formed. 3179442

10 A maximum in absorption of light was detected at the wavelength of 409 nm.

15 Another aqueous solution containing 0.3 mM FeCl_3 , 50 mM EDTA and 50 mM TRIS was prepared. In the solution the complex Fe^{3+} - EDTA - H_2O was formed. There was no maximum in absorption of light detected at the wavelength of 409 nm.

20 The above difference in result depends on that N_3^- competitively replaces one water molecule which binds to the Fe^{3+} -EDTA-complex. This in turn shows that the Fe^{3+} -EDTA-complex has a binding site, which is occupied by a dissociable water-molecule.

25 It is further known that iron catalyses the formation of hydroxyl radicals. For the formation of these the binding of one water molecule to iron is required.

30 This means that EDTA in the EDTA- Fe^{3+} -complex can not inhibit the formation of hydroxyl radicals catalysed by iron.

35 The above experiment was repeated with the difference that the EDTA was substituted with IP_3 .

No maximum in absorption was obtained at the wavelength 409 nm.

This result means that the Fe^{3+} -complex with IP_3 does not bind water. Therefore the formation of free radicals is prevented.

0179442

5 A reaction mixture consisting of 48 mmol KH_2PO_4 , 2 mmol Na-ascorbate, 0.1 mmol H_2O_2 , 0.5 mmol Fe and 1.7 mmol deoxyribose was incubated at 37°C for 1 hour. Similar reactions mixtures including EDTA 1 mmol or inositol-tri-phosphate (IP_3) 1 mmol were similarly incubated. The IP_3 used was D-myoinositol-1,2,6-triphosphate.

10

15 After incubation 1.65 ml thiobarbituric acid in 50 mmol NaOH and 1.65 ml 2.8% trichloroacetic acid was added to 2 ml of the reaction mixture. The mixture was heated to 100°C for 20 minutes and the absorbance at 532 nm was measured with water as a blank.

20 The experiments were performed with iron in the form of Fe^{2+} ($\text{Fe}(\text{NH}_4)_2\text{SO}_4$) and Fe^{3+} (FeCl_3). The results were as follows:

25

Production of free radicals catalyzed by Fe^{2+} and Fe^{3+} in the presence of IP_3 or EDTA, expressed as absorbance at 532 nm.

30

<u>Group</u>	<u>Fe^{2+}</u>	<u>Fe^{3+}</u>
Control	0.76	0.79
EDTA	2.2	1.86
IP_3	0.46	0.43

35

These results show that the formation of free radicals in the reaction mixture was diminished by 40% after addition of IP_3 . The addition of EDTA had an opposite effect. It strongly increased production of free radicals. Thus IP_3 was shown to reduce iron-dependent formation of free radicals.

0179442

Lipid peroxidation was studied in lipid micelles. The following reaction mixture was incubated for 2 hours
 5 at 37°C:

	0.4 ml	Clark-Lubs buffer pH 5.5
	0.2 ml	phospholipid liposomes
10	0.1 ml	IP ₃ 0.5-5 mM or 0.1 ml H ₂ O
	0.1 ml	Fe ²⁺ 1 mM or 0.1 ml H ₂ O
	0.1 ml	Al ³⁺ 4 mM or 0.1 ml H ₂ O
	0.1 ml	H ₂ O

The IP₃ was D-myo-inositol-1,2,6-triphosphate. After
 15 incubation, 0.5 ml of thiobarbituric acid + 0.5 ml 25%
 HCl was added and the mixture was heated at 100°C for
 15 minutes. 1 ml lubrol PX 1% (Sigma) was added and lipid
 peroxidation was measured by measuring absorbance at
 532 nm. The results were as follows:

Experiment	Concentration, mM			Absorbance 532 nm
	Fe ²⁺	Al ³⁺	IP ₃	
1	0.1	0	0	0.36
2	0	0.4	0	0.12
25	0.1	0.4	0	0.89
4	0.1	0.4	0.5	0.36
5	0.1	0	0.5	0.30
6	0.1	0	0.4	0.26
7	0.1	0	0.2	0.29
30	0.1	0	0.1	0.28
8	0.1	0	0.05	0.27
9	0.1	0	0	0.13
10	0	0	0	

Fe²⁺ caused lipid peroxidation (group 1 vs 10). Al³⁺ itself caused no peroxidation (2 vs 10) whereas the combination of Fe²⁺ + Al³⁺ caused much stronger peroxidation than Fe²⁺ alone (1 vs 3). Addition of IP₃ completely prevented the interaction between Fe²⁺ and Al³⁺ (3 vs 4). In systems with only Fe²⁺, IP₃ caused marked reduction in radical formation (1 vs 5-9).

Example 4

0179442

5 Lipid peroxidation was studied in lipid micelles. The following reaction mixture was incubated for 2 hours at 37°C:

10 0.4 ml Clark-Lubs buffer pH 5.5
 0.2 ml phospholipid liposomes
 0.1 ml IP₃ 10 mM or 0.1 ml H₂O
 0.1 ml Fe²⁺ 1 mM
 0.1 ml Cd²⁺ 1 mM or 1 ml Pb²⁺ 1 mM or 0.1 ml H₂O
 0.1 ml H₂O

15 The IP₃ was D-myo-inositol-1,2,6-triphosphate. After incubation, 0.5 ml of thiobarbituric acid + 0.5 ml 25% HCl was added and the mixture was heated at 100°C for 15 minutes. 1 ml Lubrol PX 1% (Sigma) was added and lipid peroxidation was measured by measuring absorbance at 532 nm. The results were as follows:

20

25

<u>Experiment</u>	<u>Concentration, mM</u>			<u>Absorbance</u> <u>532 nm</u>
	<u>Cd²⁺</u>	<u>Pb²⁺</u>	<u>IP₃</u>	
1	0	0	0	0.63
2	0.1	0	0	1.08
3	0.1	0	1.0	0.73
30 4	0	0.1	0	1.79
5	0	0.1	1.0	1.32

35 The lipid peroxidation caused by Fe²⁺ (group 1) was strongly increased by Cd (2) and by Pb (4). The effects of both these metals was strongly counteracted by IP₃ (3 vs 2 and 5 vs 4)

Example 5

0179442

Reaction mixtures with the following compositions were incubated for 5 minutes at 37°C:

5

KH_2PO_4 buffer pH 7.4	20mM
EDTA	0.1 mM
Salicylate	1 mM
Ascorbate	1 mM
10 H_2O_2	3.3 mM
Fe^{3+}	0.05 mM
IP ₃	0, 2.5, 5 or 10 mM

15 The products formed by oxidation of salicylate were quantified with HPLC. The IP₃ was D-myo-inositol-1,2,6-triphosphate.

20 The system studies radical scavenging. Under these reaction conditions, all Fe^{3+} will form complex with EDTA. The Fe-EDTA complex will induce free radical formation, and the ability of IP₃ to prevent oxidation of salicylate is studied.

The results of the experiment were:

25 Concentration
of IP₃, mM

Relative amount of
salicylate oxidized

0	100
2.5	44
5	43
10	19

Thus, IP₃ is able to act as a radical scavenger, thereby preventing free radical induced damage to other molecules.

Preservation of some fruits and vegetables at the addition of IP_3 .

5

4 g of fresh potatoes, bananas and apples respectively were sliced in 10 pieces each. 5 pieces of the same fruit or vegetable were put into each of 5 different beakers. Three of the beakers were filled with 15 ml of an aqueous solution of IP_3 and three additional beakers with 15 ml of an aqueous solution of IP_6 , in such a way that each 5 pieces of fruit and vegetable were exposed either to pure water or water with IP_3 and IP_6 respectively. The content of IP_3 and IP_6 respectively in the water was 1.0 g/l.

15

The samples were allowed to stand in room temperature for 15 hours. After this period the colour of the samples was inspected and the following data were found:

20

	<u>Potato</u>	<u>Banana</u>	<u>Apple</u>
	brown colour	brown colour	brown colour
25	IP ₃ added very slight brown	very slight brown	slight brown
	IP ₆ added brown colour	brown colour	brown colour

The results show that IP_3 has a preservative effect on the fruits and vegetables investigated, whereas IP_6 has no such effect.

35

Enzyme activity at the addition of IP_3 .

5 The activity of aldolase with respectively without addition of IP_3 was measured as a function of time.

10 Aldolase degrades fructose-1,6-diphosphate (FDP) to di-hydroxyacetonephosphate. This substrate is further reacted by α -glycerophosphate dehydrogenase (GDH) in the presence of nicotinamide adenine dinucleotide, reduced form (NADH) to α -glycerophosphate and nicotinamide adenine dinucleotide, oxidized form (NAD). By measuring the decline of the UV-absorption at 340 nm for the reaction NADH to NAD 15 the activity of the enzyme is determined.

20 The aldolase was stored at 25°C and the activity was measured initially and after 72 hours with and without addition of IP_3 (4 g/l).

25 0.5 μ l aldolase (A1893 from Sigma Chemical Co, 0.2 U/ml) was mixed with 2.75 ml of a buffer pH 7.5 consisting of 0.10 g KH_2PO_4 , 0.74 K_2HPO_4 , 1.96 KCH_3CH_2OO , 50 mg FDP and 8 mg NADH per 100 ml buffer. 1.47 μ l GDH was further added and the total volume was diluted to 3.0 ml. The determination of the activity was performed at 30°C.

30 The following results were obtained:

<u>Time for storage at 25°C</u>	<u>No IP_3 added</u>	<u>IP_3 added</u>	
0	0.12	0.12	
72 hours	0.05	0.07	decline of absorbance/min - " -

35 The results show that the activity of the enzyme was improved by about 40 % after addition of IP_3 when the activity was determined after 72 hours storage at 25°C.

Hydrolysis of sodium phytate with wheat phytase and fractionation of a mixture of inositolphosphates.

5 A 1.6 gram quantity of sodium phytate (from corn, Sigma Chemical Co) was dissolved in 650 ml sodium acetate buffer, pH 5.2. 2.7 gram wheat phytase (EC 3.1.3.26, 0.015 U/mg, from Sigma Chemical Co) was added and the mixture was incubated at 38°C.

10

10 The dephosphorylation was followed by determining the inorganic phosphorus released. After 3 hours when 50% inorganic phosphorus was liberated the hydrolysis was stopped by adding 30 ml ammonia to pH 12. A liquid mixture containing inositolphosphates was obtained.

15 20 350 ml of the mixture was passed through an ion-exchange column (Dowex 1, chloride form, 25 mm x 250 mm) and eluted with a linear gradient of hydrochloric acid (0-0.7 N HCl). Aliquots of eluted fractions were completely hydrolyzed in order to determine the contents of phosphorus and inositol. The peaks correspond to different inositol-phosphates i.e. a peak with the ratio of phosphorus to inositol of three to one consists of inositoltriphosphate etc. Two fractions with the ratio of phosphorus to inositol of three to one were obtained.

25 30

35

Example 9

5 Fractionation of inositoltriphosphates.

100 ml of the first fraction obtained in Example 8 with
a phosphorus/inositol ratio of three to one was neutralized and precipitated as a bariumsalt after addition
10 of 10 % excess of 0.1 M bariumacetate solution. 600 mg
of the precipitated salt was dissolved in 50 ml diluted
hydrochloric acid. The solution was separated on an ion-
exchange column (Dowex 1, chloride form, 25 mm x 2500
15 mm) with diluted hydrochloric acid as eluent. Aliquots
of eluted fractions were analyzed for phosphorus. Three
peaks consisting of isomers of inositoltriphosphates
can be seen.

20

25

30

Example 10

5 Structural determination of isomers of inositol-triphosphates with NMR.

10 The three peaks obtained in Example 9 were analyzed by H-NMR. Data show that the peaks consist of myo-inositol-1.2.6-triphosphate, myo-inositol-1.2.3-triphosphate and myo-inositol-1.3.4-triphosphate respectively.

15 The second fraction obtained in Example 18 with a phosphorus/inositol ratio of three to one was analyzed by H-NMR. Data show that the fraction consists of myo-inositol-1.2.5-triphosphate.

20

25

30

35

Example 11

Determination of optical isomers of inositol-triphosphates.

5 20 mg of the compounds determined with NMR according to Example 10 to be myo-inositol-1.2.6-triphosphate and myo-inositol-1.3.4-triphosphate were further chromatographed on a chiral column based on acetylated cellulose (20 mm x 300 mm from Merck) with a mixture of ethanol and water as eluent. The fractions were analyzed with a polarimeter. As can be seen each compound consists of one optical isomer, D-myoinositol-1.2.6-triphosphate and L-myoinositol-1.3.4-triphosphate respectively.

15

20

25

30

Example 12

Hydrolysis of sodium phytate with baker's yeast and fractionation of a mixture of inositolphosphates.

10 A 0.7 gram quantity of sodium phytate (from corn, Sigma Chemical Co) was dissolved in 600 ml sodium acetate buffer pH 4.6. 50 gram of baker's yeast from Jästbolaget, Sweden (dry substance: 28 %, nitrogen content: 2 %; phosphorus content: 0.4 %) was added with stirring and incubation was continued at 45°C. The dephosphorylation was followed by determining the inorganic phosphorus released. After 15 7 hours when 50% inorganic phosphorus was liberated the hydrolysis was stopped by adding 30 ml of ammonia to pH 12. The suspension was centrifuged and the supernatant was collected.

20 400 ml of the supernatant was passed through an ion-exchange column (Dowex 1, chloride form, 25 mm x 250 mm) and eluted with a linear gradient of hydrochloric acid (0-0.7 N HCl).

25 Aliquots of eluted fractions were completely hydrolyzed
in order to determine the contents of phosphorus and
inositol. The peaks correspond to different inositol-
phosphates i.e. a peak with the ratio of phosphorus to
inositol of three to one consists of inositoltriphosphates
etc.
30

Example 13

Structural determination of isomers of inositoltriphosphate.

5 The fraction obtained in Example 12 with a phosphorus/inositol ratio of three to one was neutralized and evaporated before analysis with H-NMR. Data show that the peak consists of myo-inositol-1.2.6-triphosphate.

10

Example 14

15 Determination of optical isomers of myo-inositol-triphosphate.

The same method was used as described in Example 11 with the difference that 10 mg of the compound determined
20 with NMR according to Example 13 was analyzed. As can be seen the compound consists of one optical isomer, D-myoinositol-1.2.6-triphosphate.

25

30


35

For purposes of further understanding the invention, formulas are given below of some of the IP_3 -isomers of the invention. Formulas are also given for IP_6 , IP_5 , IP_4 and IP_2 .


5

The lower phosphate-esters of myoinositol are named depending on where the phosphoric acid groups are situated on the inositol ring, with the numbering giving as low position numbers as possible. L and D stand for clockwise and counterclock-wise counting respectively, and are used depending on which result gives the lowest position number. The carbon atom which has an axial phosphoric acid group always has the position number 2. The structural formulae below are simplified to the acid form.


15.

myo-inositol; $C_6H_6(OH)_6$

20




25



30


1.2.3.4.5.6-hexakis-(dihydrogen-phosphate)-myo-inositol alternatively myo-inositol hexakis (phosphate) or IP_6

35




D-myo-inositol-1.2.6-triphosphate alternatively D-1.2.6- IP_3


0179442



5




10




15




20



25



30



D-myoinositol-1,2,5-triphosphate alternatively
D-1,2,5-IP₃

myo-inositol-1,2,3-triphosphate alternatively
1,2,3-IP₃

L-myoinositol-1,3,4-triphosphate alternatively
L-1,3,4-IP₃

L-myoinositol-1,2-diphosphate alternatively L-1,2-IP₂

D-myoinositol-1,2,5,6-tetra-phosphate or D-1,2,5,6-IP₄

L-myoinositol-1,2,3,4,5-penta phosphate or
L-1,2,3,4,5-IP₅

These IP₃ compounds are described and prepared in applicant's simultaneously filed patent application with the title "Inositoltriphosphate" (applicant's file no. 355 b (42762) copy of which is attached.

CLAIMS

0179442

1. A stabilized composition comprising an organic substrate subject to degradation by oxidation and/or free radicals, characterized in that the composition contains a stabilizing amount of inositoltriphosphate (IP₃).
5
2. A composition according to claim 1, wherein the organic substrate is a pharmaceutical or biological system.
10
3. A composition according to claim 2, wherein the pharmaceutical is selected from the group consisting of insulin, vaccine, hyaluronic acid, intralipid and prostaglandin.
15
4. A composition according to claim 2, wherein the biological system is selected from the group consisting of nucleic acids, carbohydrates, lipids and proteins.
20
5. A composition according to claim 1 containing additionally a minor amount of inositoltetraphosphate (IP₄) and inositol-diphosphate (IP₂).
25
6. A composition according to claim 1, wherein the IP₃ contains at least one of D-myo-inositol-1.2.6-triphosphate, D-myo-inositol-1.2.5-triphosphate, myoinositol-1.2.3-triphosphate, D-myo-inositol-1.4.5-triphosphate and L-myo-inositol-1.3.4-triphosphate.
30
7. A composition according to claim 6, wherein the IP₃ is a salt, the cation of which is selected from the group consisting of alkali metals and alkaline earth metals.
35
8. A method of stabilizing an organic substrate subject to oxidative or free radical degradation, which comprises adding thereto a stabilizing amount of IP₃.

9. A method according to claim 8, wherein the organic substrate
is a pharmaceutical or biological system. 0179442

10. A method according to claim 8, wherein the pharmaceutical
5 is selected from the group consisting of insulin, vaccine,
hyaluronic acid, intralipid and prostaglandin.

11. A method according to claim 8, wherein the biological system
10 is selected from the group consisting of DNA, RNA, nucleic
acids, biological tissue, carbohydrates, lipids, protein
such as enzyme, micro-organisms, seeds, plant parts,
spores, fruits and food stuffs.

12. A method according to claim 8, wherein additionally a minor
15 amount of inositoltetraphosphate (IP₄) and inositoldiphosphate (IP₂) is added.

13. A method according to claim 8, wherein the IP₃ contains at
20 least one of D-myo-inositol-1.2.6-triphosphate, D-myo-
inositol-1.2.5-triphosphate, myoinositol-1.2.3-triphosphate,
D-myo-inositol-1.4.5-triphosphate and L-myo-inositol-1.3.4-
triphosphate.

14. A method according to claim 8, wherein the IP₃ is a salt,
25 the cation of which is selected from the group consisting
of alkali metals and alkaline earth metals.



EP 85 11 3384

DOCUMENTS CONSIDERED TO BE RELEVANT

DOCUMENTS CONSIDERED TO BE RELEVANT									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)						
D, A	US-A-2 723 938 (F.H. BUCKWALTER) * Whole document *	1	A 61 K 47/00 A 23 L 3/34 C 07 F 9/117						
A	JP-B-69 023 516 (EISAI CO., LTD) * Whole document *	1							
<table border="1"> <thead> <tr> <th colspan="2">TECHNICAL FIELDS SEARCHED (Int. Cl. 4)</th> </tr> </thead> <tbody> <tr> <td colspan="2">A 23 L 3/00 A 61 K 47/00 C 07 F 9/00</td> </tr> </tbody> </table>				TECHNICAL FIELDS SEARCHED (Int. Cl. 4)		A 23 L 3/00 A 61 K 47/00 C 07 F 9/00			
TECHNICAL FIELDS SEARCHED (Int. Cl. 4)									
A 23 L 3/00 A 61 K 47/00 C 07 F 9/00									
<p>The present search report has been drawn up for all claims</p> <table border="1"> <thead> <tr> <th>Place of search</th> <th>Date of completion of the search</th> <th>Examiner</th> </tr> </thead> <tbody> <tr> <td>THE HAGUE</td> <td>21-01-1987</td> <td>BESLIER L.M.</td> </tr> </tbody> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	21-01-1987	BESLIER L.M.
Place of search	Date of completion of the search	Examiner							
THE HAGUE	21-01-1987	BESLIER L.M.							
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons B : member of the same patent family, corresponding document</p>									

The present search report has been drawn up for all claims.

Place of search

Date of completion of the search

Examiners

CATEGORY OF CITED DOCUMENTS

X. PARTICULARS OF OWNERSHIP

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the case

A technological background

R: technological background
O: non-written disclosure

P : intermediate document

INTERVIEWER'S DOCUMENT

T : theory or principle underlying the invention
E : enables patent

E. earlier patent document, but published on, or after the filing date

D document cited in the application
L document cited for ref.

L document cited for other reasons

• member of the same category

2. Member of the same patent family, corresponding document